Caption Management’s Amneal Pharmaceuticals AMRX Stock Holding History

Caption Management’s Portfolio AMRX Stock Details AMRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-81,735	Closed	-$1.03M	–	1518
2025 Q4	$1.03M	Buy	+81,735	New	+$935K	0.01%	1044

Other funds holding AMRX

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

TGA

TPG GP A Fort Worth, Texas $5B AUM 58.56% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

RCMNY

Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Neuberger Berman Group New York $150B AUM 40.08% 1-Year Est. Return

Caption Management's AMRX Position: Q1 2026 in Review

Caption Management sold out of Amneal Pharmaceuticals (AMRX) in Q1 2026, closing a stake of 81,735 shares — an estimated $1.03M sold.

Caption Management first reported a position in AMRX in Q4 2025 and held it in 1 quarter. The position peaked at $1.03M in Q4 2025. 317 funds tracked by Wall St. Rank hold AMRX as of Q1 2026.

Caption Management reported no remaining Amneal Pharmaceuticals position as of Q1 2026 after selling out during the quarter.
Caption Management sold 81,735 Amneal Pharmaceuticals shares in Q1 2026, an estimated $1.03M.
Caption Management first reported a position in Amneal Pharmaceuticals in Q4 2025 and held it in 1 quarter.
Caption Management's Amneal Pharmaceuticals position peaked at $1.03M in Q4 2025.
317 funds tracked by Wall St. Rank held Amneal Pharmaceuticals as of Q1 2026.

Based on Caption Management's 13F filing for Q1 2026, filed 15 May 2026.